摘要
目的:探讨人鼻咽癌(nasopharyngeal carcinoma,NPC)细胞株中表皮生长因子受体(epidermal growth factor receptor,EGFR)蛋白的表达水平与西妥昔单抗细胞抑制率的相关性。方法:用蛋白质印迹法检测人NPC细胞株CNE-1、CNE-2、HONE-1、C-666、SUNE-1、5-8F以及HNE-1共7种细胞株中EGFR蛋白的表达水平,用MTT法检测西妥昔单抗对细胞株的抑制率。结果:西妥昔单抗浓度为1500μg/mL时,EGFR蛋白表达水平与抑制率呈正相关(r=0.444,P=0.044),西妥昔单抗浓度增加至1800μg/mL时,两者呈负相关(r=-0.468,P=0.032)。结论:在NPC细胞株中,EGFR蛋白表达水平与西妥昔单抗的细胞抑制率之间无相关性,EGFR蛋白表达水平不能作为预测西妥昔单抗疗效的指标。
Objective：To study the correlation between epidermal growth factor receptor（EGFR） expression and inhibition ra- tios of eetuximab in human nasopharyngeal carcinoma cell lines. Methods： The level of EGFR protein expression of several hu man nasopharyngeal carcinoma cell lines, including CNE-1, CNE2, HONE-1, C-666, SUNE-1, 5-8F and HNE-1 were detec- ted by Western blotting. The cell inhibition ratios of cetuximab were measured using MTT method. Results： When the density of cetuximab was 15009g/mL, there was significant positive correlation between EGFR protein expression and inhibition ratio of cetuximab（r= 0. 444, P = 0. 044）. However, there was significant negative correlation when the density was 1800μg/mL （r= -0. 468, P= 0. 032）. Conclusions： There is no correlation between EGFR protein expression and inhibition ratios of cetu ximab, and the level of EGFR protein expression can＇t serve as a marker in predicting the therapeutic effect of cetuximab.
出处
《中国临床医学》
2012年第6期582-584,共3页
Chinese Journal of Clinical Medicine
基金
广东省自然科学基金(编号:S2011040003062)
南方医院院长基金(编号:2009C028)
关键词
西妥昔单抗
鼻咽癌
表皮生长因子受体
Cetuximab
Nasopharyngeal carcinoma
Epidermal growth factor receptor
